A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Sapanisertib (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 13 Apr 2017 Planned primary completion date changed from 1 Oct 2017 to 31 Oct 2017.
- 06 Feb 2017 Status changed from not yet recruiting to recruiting.
- 24 Sep 2016 New trial record